Frank Gerome Appointed Chief Executive Officer of Endothelix, Inc.

 

Houston, TX, Jan 4th – Endothelix, Inc. announces that effective January 1, 2008 its Board of Directors has named Frank Gerome to serve as interim Chief Executive Officer. Mr. Gerome will succeed company founder, Dr. Morteza Naghavi, who will continue to serve as Chairman of the Board.

“This is an exciting time for Endothelix. The Company has received FDA approval for its first product and will be entering the market during the first quarter of 2008. In support of the product launch we will be expanding our sales and marketing team. In addition, we will be closing on our Series A financing this month and we have begun development of our next major product focused on the clinical market. Endothelix is bringing important screening and monitoring technology to the cardiovascular health arena and I am pleased to be part of this effort. I also look forward to becoming an active participant in the Houston life sciences community,” stated Mr. Gerome.

"We're delighted to have Frank Gerome join Endothelix and look forward to a successful New Year with his leadership" said Morteza Naghavi, M.D., founder and chairman of the Board.

Frank Gerome has been active as an advisor with Endothelix and is a Partner with STARTech Early Ventures, a seed-stage venture capital firm. He is responsible for managing the medical technology and healthcare investment activity at STARTech. While maintaining his activities at STARTech, Frank previously served as Chief Operating Officer and Chief Financial Officer of a STARTech portfolio company, Reata Pharmaceuticals, Inc. Mr. Gerome holds a BS degree from the University of Southern California and an MBA from Pepperdine University. He served as an officer in United States Navy following graduation from college.

About Endothelix, Inc

Endothelix is a Delaware corporation based in Houston, Texas and formed in December 2003.  The company is positioned as the first to incorporate non-invasive, non-imaging micro and macro vascular (endothelial -dependent and –independent) function monitoring technologies into the existing risk factor assessment to help physicians more accurately monitor their patients’  cardiovascular health, and to use appropriate therapies for the prevention and treatment of heart attack and stroke.

Visit www.endothelix.com for more information.

Author: Robin Owen, PhD.
Phone: (713) 529-2599
Email:
Category: client companies | Sub Category: news